{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:31:56Z","timestamp":1740130316095,"version":"3.37.3"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"AbbVie Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,23]]},"DOI":"10.1093\/rheumatology\/keac388","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T05:07:07Z","timestamp":1657256827000},"page":"e1-e3","source":"Crossref","is-referenced-by-count":1,"title":["Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby","family":"Garrood","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Guy\u2019s and St. Thomas\u2019 Foundation Trust , London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Gullick","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Coventry and Warwickshire , Coventry"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Helliwell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby","family":"Kent","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, AbbVie Ltd , Maidenhead"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Marks","sequence":"additional","affiliation":[{"name":"Christchurch Hospital, University Hospitals Dorset NHS Foundation Trust , Christchurch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Royal National Hospital for Rheumatic Diseases, University of Bath , Bath"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daljit","family":"Kaur-Papadakis","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, AbbVie Ltd , Maidenhead"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Tahir","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and General Medicine, Barnet Hospital, Royal Free London NHS Trust , Barnet"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn","family":"van Haaren","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, AbbVie Ltd , Maidenhead"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection Immunity and Inflammation, University of Glasgow College of Medical Veterinary Sciences , Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"2022122410105445900_keac388-B1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40744-021-00305-z","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 Study","volume":"8","author":"Mease","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2022122410105445900_keac388-B2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: ELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022122410105445900_keac388-B3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"2022122410105445900_keac388-B4","article-title":"P174 Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC","volume":"60(Suppl 1)","author":"Coates","year":"2021","journal-title":"Rheumatology"},{"key":"2022122410105445900_keac388-B5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"2022122410105445900_keac388-B6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/annrheumdis-2020-eular.1229","article-title":"Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2): a double-blind, randomized controlled phase 3 trial","volume":"79","author":"Genovese","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022122410105445900_keac388-B7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40744-021-00410-z","article-title":"Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials","volume":"9","author":"Burmester","year":"2022","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac388\/45059328\/keac388.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/1\/e1\/48396214\/keac388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/1\/e1\/48396214\/keac388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T10:11:06Z","timestamp":1671876666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/1\/e1\/6633739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,7,7]]},"published-print":{"date-parts":[[2022,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac388","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,7,7]]}}}